trial
as of 2026-07-01Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations
NCTId NCT07121868
at a glance
Phase 1 · Completed
Enrollment 29 (actual)
Sponsored by Aya Mohammed Abdel Magid Abdel Hamid
Primary completion 2025-01-23
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
None
Start
2024-08-03
Primary completion
2025-01-23
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Aya Mohammed Abdel Magid Abdel HamidLead Sponsor
Advanced Research Center (ARC)Collaborator
Atco Pharma for Pharmaceutical IndustriesCollaborator
Investigators
1
Kamal A. Badr, PhDStudy Director
Sites
1 total
Cairo, Egypt
Facts & assertions
4 sourced
Enrollment
29
Phase
PHASE1
Primary Completion Date
2025-01-23
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
indication
indication
investigator
person